A placebo-controlled study for SPM 962 in RLS patients.

Trial Profile

A placebo-controlled study for SPM 962 in RLS patients.

Phase of Trial: Phase II

Latest Information Update: 21 May 2016

At a glance

  • Drugs Rotigotine (Primary)
  • Indications Restless legs syndrome
  • Focus Therapeutic Use
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 15 Jan 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jan 2010 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
    • 14 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top